{Replace with the Title of Your Dissertation}
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A Poetic Narrative Inquiry Into the Lives of People with Lyme Disease
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Cardinal Scholar A POETIC NARRATIVE INQUIRY INTO THE LIVES OF PEOPLE WITH LYME DISEASE A DISSERTATION SUBMITTED TO THE GRADUATE SCHOOL IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE DOCTOR OF EDUCATION IN ADULT, HIGHER, AND COMMUNITY EDUCATION BY AMY M. BAIZE-WARD DISSERTATION ADVISOR: DR. MICHELLE GLOWACKI-DUDKA BALL STATE UNIVERSITY MUNCIE, INDIANA DECEMBER 2018 A POETIC NARRATIVE INQUIRY INTO THE LIVES OF PEOPLE WITH LYME DISEASE A DISSERTATION SUBMITTED TO THE GRAD SCHOOL IN PARTICAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE DOCTOR OF EDUCATION IN ADULT, HIGHER, AND COMMUNITY EDUCATION BY AMY M. BAIZE-WARD DISSERTATION ADVISOR: DR. MICHELLE GLOWACKI-DUDKA APPROVED BY: __________________________________________ __________ Michelle Glowacki-Dudka, Committee Chairperson Date ____________________________________ __________ Bo Chang, Department Representative Date __________________________________________ __________ Amanda Latz, Cognate Representative Date ___________________________________________ _________ James Jones, At Large Committee Member Date BALL STATE UNIVERSITY MUNCIE, IN DECEMBER 2018 Copyright © December 2018 Amy M. Baize-Ward All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the author. DEDICATION I have struggled for many years realizing that I could no longer share my story through song. I found my voice again, only this time through the power of the written word. That would never have happened without walking through my own journey with Lyme disease and believing in the path that God has for my life. -
Peer-Reviewed Evidence of Persistence of Lyme Disease
Peer-Reviewed Evidence of Persistence of Lyme Disease Spirochete Borrelia burgdorferi and Tick-Borne Diseases The following is a list of over 700 peer-reviewed articles that support the evidence of persistence of Lyme and other tick-borne diseases. It is organized into different categories—general, neuropsychiatric, dementia and congenital transmission. General: Persistence of Lyme Disease Spirochete Borrelia burgdorferi 1. Abele DC, Anders KH. The many faces and phases of borreliosis. J Am Acad Dermotol 1990; 23:401-410. [chronic Lyme borreliosis]. 2. Aberer E, Klade H. Cutaneous manifestations of Lyme borreliosis. Infection 1991; 19: 284-286. [chronic Lyme borreliosis]. 3. Aberer E, Breier F, Stanek G, and Schmidt B. Success and failure in the treatment of acrodermatitis chronica atrophicans skin rash. Infection 1996; 24: 85-87. 4. Aberer E, Kersten A, Klade H, Poitschek C, Jurecka W. Heterogeneity of Borrelia burgdorferi in the skin. Am J Dermatopathol 1996; 18(6): 571-519. 5. Akin E, McHugh Gl, Flavell RA, Fikrig E, Steere AC. The immunoglobulin (IgG) antibody response to OspA and OspB correlates with severe and prolonged Lyme arthritis and the IgG response to P35 with mild and brief arthritis. Infect Immun 1999; 67: 173- 181. 6. Albert S, Schulze J, Riegel H, Brade V. Lyme arthritis in a 12-year-old patient after a latency period of 5 years. Infection 1999; 27(4-5): 286-288. 7. Allred DR. Babesiosis: persistence in the face of adversity. Trends Parasitol. 2003;19:51– 55. 8. Al-Robaiy S, Dihazi H, Kacza J, et al. Metamorphosis of Borrelia burgdorferi organisms―RNA, lipid and protein composition in context with the spirochete’s shape. -
Lyme Disease: a Comprehensive Approach to an Evolving Threat
S. HRG. 112–632 LYME DISEASE: A COMPREHENSIVE APPROACH TO AN EVOLVING THREAT FIELD HEARING OF THE COMMITTEE ON HEALTH, EDUCATION, LABOR, AND PENSIONS UNITED STATES SENATE ONE HUNDRED TWELFTH CONGRESS SECOND SESSION ON EXAMINING LYME DISEASE, FOCUSING ON A COMPREHENSIVE APPROACH TO AN EVOLVING THREAT AUGUST 30, 2012 (Stamford, CT) Printed for the use of the Committee on Health, Education, Labor, and Pensions ( Available via the World Wide Web: http://www.gpo.gov/fdsys/ U.S. GOVERNMENT PRINTING OFFICE 75–786 PDF WASHINGTON : 2012 For sale by the Superintendent of Documents, U.S. Government Printing Office Internet: bookstore.gpo.gov Phone: toll free (866) 512–1800; DC area (202) 512–1800 Fax: (202) 512–2104 Mail: Stop IDCC, Washington, DC 20402–0001 COMMITTEE ON HEALTH, EDUCATION, LABOR, AND PENSIONS TOM HARKIN, Iowa, Chairman BARBARA A. MIKULSKI, Maryland MICHAEL B. ENZI, Wyoming JEFF BINGAMAN, New Mexico LAMAR ALEXANDER, Tennessee PATTY MURRAY, Washington RICHARD BURR, North Carolina BERNARD SANDERS (I), Vermont JOHNNY ISAKSON, Georgia ROBERT P. CASEY, JR., Pennsylvania RAND PAUL, Kentucky KAY R. HAGAN, North Carolina ORRIN G. HATCH, Utah JEFF MERKLEY, Oregon JOHN MCCAIN, Arizona AL FRANKEN, Minnesota PAT ROBERTS, Kansas MICHAEL F. BENNET, Colorado LISA MURKOWSKI, Alaska SHELDON WHITEHOUSE, Rhode Island MARK KIRK, IIllinois RICHARD BLUMENTHAL, Connecticut PAMELA J. SMITH, Staff Director, Chief Counsel LAUREN MCFERRAN, Deputy Staff Director FRANK MACCHIAROLA, Republican Staff Director (II) CONTENTS STATEMENTS THURSDAY, AUGUST 30, 2012 Page Blumenthal, Hon. Richard, a U.S. Senator from the State of Connecticut, opening statement ................................................................................................ 1 Gillibrand, Hon. Kirsten E., a U.S. Senator from the State of New York ......... -
Morgellons: an Exercise in Medical Validation Introduction
Harry Quinn Schone Morgellons: an exercise in medical validation Introduction Morgellons may or may not be a modern affliction, but the circumstances in which it exists are distinctly specific to the 21st century.1 The existing literature is both sparse and voluminous. Medical journal work is lacking, whilst patientwritten material stretches all over the internet.2 Almost totally absent is an academic effort which tries to document what has happened from a social constructivist position, taking account of both accredited literature and otherwise. In the following piece I hope to go some way towards filling this gap, and so I will now briefly outline my point of view. I do not believe it is necessary to engage in complex and often circular debates about aetiology. Remove this dangerous temptation and what is left is the processes: who is made to feel how and by what means; what makes a ‘disease’, what is ‘medical authority’ and how does it exercise said authority? These are the questions I hope to answer. Neutrality is impossible, but hopefully by aiming towards it I can achieve something close to meaningful analysis as a byproduct of such efforts. To this end I have attempted to regard both academic and nonacademic sources as valuable. ‘Sticking to the literature’ in this case would I believe prove myopic and do a disservice to the heterogeneity of the actors involved. In short, I am not concerned so much with the symptoms and the various causal debates, but rather with the way that Morgellons illustrates power structures between patients and the medical community. -
Calendar No. 238
Calendar No. 238 110TH CONGRESS " ! REPORT 1st Session SENATE 110–107 DEPARTMENTS OF LABOR, HEALTH AND HUMAN SERVICES, AND EDUCATION, AND RELATED AGENCIES APPROPRIATION BILL, 2008 R E P O R T OF THE COMMITTEE ON APPROPRIATIONS U.S. SENATE ON S. 1710 JUNE 27, 2007.—Ordered to be printed Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Bill, 2008 (S. 1710) Calendar No. 238 110TH CONGRESS REPORT " ! 1st Session SENATE 110–107 DEPARTMENTS OF LABOR, HEALTH AND HUMAN SERV- ICES, AND EDUCATION, AND RELATED AGENCIES APPRO- PRIATION BILL, 2008 JUNE 27, 2007.—Ordered to be printed Mr. HARKIN, from the Committee on Appropriations, submitted the following REPORT [To accompany S. 1710] The Committee on Appropriations reports the bill (S. 1710) mak- ing appropriations for Departments of Labor, Health and Human Services, and Education and related agencies for the fiscal year ending September 30, 2008, and for other purposes, reports favor- ably thereon and recommends that the bill do pass. Amount of budget authority Total of bill as reported to the Senate ............. $605,536,474,000 Amount of 2007 appropriations ........................ 545,857,321,000 Amount of 2008 budget estimate ...................... 596,378,249,000 Bill as recommended to Senate compared to— 2007 appropriations .................................... ∂59,679,153,000 2008 budget estimate ................................. ∂9,158,225,000 36–285 PDF CONTENTS Page Summary of Budget Estimates and Committee Recommendations ................... -
Healing with Magnets by Gary Null, Ph.D
Healing With Magnets By Gary Null, Ph.D. With Vicki Riba Koestler Biomagnetic therapy is not a new to everyone. Many veterinarians have been aware of biomagnetic benefits for years, and use magnets to heal fractures quickly, thereby saving the lives of racehorses and other animals. Doctors treating professional athletes commonly recommend magnets to speed up recovery from painful injuries. And other physicians in a variety of specialties, including dermatologists, internists, pediatricians, and surgeons, are seeing excellent results as well That magnetic healing is nothing new can be seen by looking at early records of scientifically advanced civilizations, which tell us that magnetic forces have long been prized for their restorative properties. Ancient Greece discovered the very first natural magnet in the form of the lodestone, said Hippocrates, the father of medicine, noted its healing power. The Egyptians, too, described the divine powers of the magnet in their writings, and Cleopatra frequently adorned herself with magnetic jewelry to preserve her youthfulness. Chinese manuscripts dating back thousands of years describe the Eastern belief that the life force, termed qi , is generated by the earth’s magnetic field. Today, many believe that certain places on earth, such as Lourdes, France, and Sedona, Arizona, owe their healing powers to naturally high levels of this qi , or biomagnetic energy. Finally, no one claims that magnetic therapy is going to work for everyone. However, ample clinical and personal evidence suggests that people experience a beneficial effect. One is led to ponder whether when Hippocrates wrote, “The natural force within each of us is that greatest healer of all,” he did not have magnetic energy in mind. -
BOCEAN™ TEST* Manual *Transcutaneous–Electro-Supplement Therapy
BOCEAN™ TEST* Manual *Transcutaneous–Electro-Supplement Therapy Making HOCL (Hypochlorous Acid) supplement IN the body Page 1 of 42 Table of Contents INTRODUCTION ............................................................................................................................................................... 5 WHAT DOES TRANSCUTANEOUS-ELECTROTHERAPY DO? ................................................................................................. 6 SUPPLIES NECESSARY FOR THE COURSE ........................................................................................................................... 7 • BASIC PORTABLE UNIT: ................................................................................................................................... 7 o 9 V batteries................................................................................................................................................... 7 o AA OR AAA BATTERY HOLDERS: https://www.ebay.com/sch/i.html?_from=R40&_nkw=AAA+Batteries+Case+wire+lead&_sacat=0&LH_TitleDesc=0& LH_PrefLoc=1&_sop=15 ........................................................................................................................................... 7 • FIXED UNIT: ....................................................................................................................................................... 7 o 6-Volt lantern battery or a 9-volt -buy at a local store ............................................................................. 7 o OR a USB -
Prevalence of Lyme Disease in the US Is 10-Times Higher Than
Prevalence of Lyme Disease in the US Is 10-Times Higher Than Previously Reported By Dr. Mercola It‟s now been fairly well-established that chronic inflammation is an underlying factor in most chronic illnesses. Diseases, such as Parkinson's, multiple sclerosis, cardiomyopathy, gastritis, and chronic fatigue, are all turning out to be expressions of chronic infections. Lyme disease appears to be a major, yet oftentimes hidden, player. This may sound shocking to you, but diagnosing Lyme is very difficult, so the actual number of cases is high relative to reporting. According to preliminary statistics1, 2 just released by the Centers for Disease Control and Prevention (CDC), approximately 300,000 new cases of Lyme disease are diagnosed in the US each year. This is about 10 times higher than the officially reported number of cases, indicating that the disease is being vastly underreported. The data was presented by CDC officials at the 2013 International Conference on Lyme Borreliosis and Other Tick-Borne Diseases in Boston in the middle of August. As reported in the featured article by Medical News Today3: “This agrees with studies reported in the 1990s that showed the actual number of Lyme diseases cases in the US was likely to be three to twelve times higher than reported... Lyme disease is the most commonly reported tick-borne illness in the US.” What Is Lyme disease? Lyme disease was named after the East Coast town of Lyme, Connecticut, where the disease was first identified in 1975.4 The disease was first referred to as "Lyme arthritis" due to the presentation of atypical arthritic symptoms in children that lived in that city. -
Morgellons Disease Open Access to Scientific and Medical Research DOI
Journal name: International Journal of General Medicine Article Designation: Review Year: 2016 Volume: 9 International Journal of General Medicine Dovepress Running head verso: Middelveen and Stricker Running head recto: Morgellons Disease open access to scientific and medical research DOI: http://dx.doi.org/10.2147/IJGM.S116608 Open Access Full Text Article REVIEW Morgellons disease: a filamentous borrelial dermatitis Marianne J Middelveen Abstract: Morgellons disease (MD) is a dermopathy characterized by multicolored filaments Raphael B Stricker that lie under, are embedded in, or project from skin. Although MD was initially considered to be a delusional disorder, recent studies have demonstrated that the dermopathy is associated with International Lyme and Associated Diseases Society, Bethesda, MD, USA tickborne infection, that the filaments are composed of keratin and collagen, and that they result from proliferation of keratinocytes and fibroblasts in epithelial tissue. Culture, histopathologi- cal and molecular evidence of spirochetal infection associated with MD has been presented in several published studies using a variety of techniques. Spirochetes genetically identified as Borrelia burgdorferi sensu stricto predominate as the infective agent in most of the Morgellons skin specimens studied so far. Other species of Borrelia including Borrelia garinii, Borrelia miyamotoi, and Borrelia hermsii have also been detected in skin specimens taken from MD Video abstract patients. The optimal treatment for MD remains to be determined. Keywords: Morgellons disease, dermatitis, Lyme disease, Borrelia burgdorferi, spirochetes Introduction Morgellons disease (MD) is an emerging dermopathy with worldwide distribution. The name “Morgellons” is derived from a disease recognized in the seventeenth cen- tury in French children by Sir Thomas Browne. -
BOOKTIVISM: the Power of Words
BOOKTIVISM: The Power of Words Book•ti•vi•sm(noun). 1. The mobilization of groups of concerned citizens produced by reading books offering powerful analyses of social or political issues. 2. A call to action based on the sharing of knowledge through books. 3. Books + activism = “booktivism.” 4. A term first used at the SellingSickness, 2013: People Before Profits conference in Washington, DC, see www.sellingsickness.com. Read. Discuss. Be thoughtful. Be committed. Here are some more suggestions to get you started: 1) Set up a reading group on disease-mongering among interested friends and colleagues. If you do The books included in BOOKTIVISM celebrate recent contributions to the broad topic of disease- not already have a group of interested readers, post a notice in your workplace, library, community mongering, especially as they examine the growing prevalence and consequences of overtreatment, center, apartment building, etc. Once you have a group, decide where to meet. Book clubs can overscreening, overmarketing, and overdiagnosis (see Lynn Payer’s 1992 classic, Disease-Mongers: How meet anywhere – at homes, in dorms, in pubs, in coffeehouses, at libraries, even online! Decide on Doctors, Drug Companies, and Insurers Are Making You Feel Sick, for an introduction to timing and format. Will you meet monthly/bimonthly? You’ll need time to prepare for the sessions, disease-mongering). but not so much time that you lose touch. Circulate the reading guide. It is usually best if one person leads each discussion, to have some questions at the ready and get things rolling. Although the challenge to disease-mongering is not unprecedented (the women’s health movement of the 1970s was another key historical moment), these books represent an impressive groundswell OR, maybe you’d like to of amazing, powerful, brilliant, and often deeply unsettling investigations by physicians, health scientists, 2) Set up a lecture/discussion group. -
Normal Laboratory Values/Adult Patients
Normal Laboratory Values/Adult Patients Clinical Chemistry Tests Lipid Panel Alanine aminotransferase 13–48 U/L Cholesterol, total 160–240 mg/dL (ALT, SGPT) HDL cholesterol >40 mg/dL Albumin 3.6–5.2 g/dL LDL cholesterol <130 mg/dL Alkaline phosphatase (ALP) 35–120 U/L Triglycerides 55–200 mg/dL Amylase, serum 44–128 U/L Aspartate aminotransferase 15–41 U/L (AST, SGOT) Bilirubin, conjugated 0–0.2 mg/dL Thyroid Function Tests Bilirubin, total 0.2–1.2 mg/dL Thyroid stimulating hormone (TSH) 2–11 μU/mL Calcium 8.5–10.5 mg/dL Thyroxine, free (FT4) 0.8–2.4 ng/dL Carbon dioxide (CO2), total 23–30 mEq/L Thyroxine, total (T ) 4.0–12.0 μg/dL Chloride 98–109 mEq/L 4 Triiodothyronine (T )70–200 ng/dL Creatine kinase (CK, CPK) 40–260 U/L 3 Triiodothyronine (T ) resin uptake 25–38% Creatinine 0.7–1.2 mg/dL 3 (T3RU) Gamma glutamyltransferase 5–40 U/L (GGT) Glucose, fasting 65–110 mg/dL Hemoglobin A1C 5.0–7.0% of total Hb Blood Gases Iron, serum 50–170 μg/dL Iron-binding capacity, total 270–390 μg/dL Arterial Venous (TIBC) Base excess À3.0 to À5.0 to Lactate, serum (venous) 5.0–20.0 mg/dL +3.0 mEq/L +5.0 mEq/L Lactate dehydrogenase (LDH) 110–260 U/L Bicarbonate 18–25 mEq/L 18–25 mEq/L Lipase 10–140 U/L (HCO3) – – Magnesium 1.5–2.5 mg/dL pO2 80 95 mm Hg 30 48 mm Hg – – Potassium 3.5–5.1 mEq/L O2 saturation 95 98 % 60 85 % – – Prostate-specific antigen 0–4 ng/mL pCO2 34 45 mm Hg 35 52 mm Hg – – Protein, total 6.1–7.9 g/dL Total CO2 23 30 mEq/L 24 31 mEq/L – – Sodium 136–147 mEq/L pH 7.35 7.45 7.32 7.42 Troponin I <2.5 ng/mL Troponin T <0.2 ng/mL Urea nitrogen 6.0–20.0 mg/dL Hematology and Coagulation Tests Uric acid 2.6–7.2 mg/dL White blood cell (WBC) 4.4–11.0 K/mm3 count Hemoglobin 12.2–15.0 g/dL (continued) # Springer International Publishing Switzerland 2017 1811 P.M. -
Comment from Universal Health Coverage to Right Care for Health
Comment THELANCET-D-16-08652 REQUESTED [PII_REPLACE] Embargo: January 8, 2017—23:30 (GMT) From universal health coverage to right care for health Achieving universal health coverage is the most happen side-by-side in different countries, within Published Online important means to advance health and wellbeing during countries, among populations, within institutions, January 8, 2017 http://dx.doi.org/10.1016/PII the next decade. Too many countries—and not only in and even for a single person. This situation offers an low-income or middle-income settings—do not have a enormous (and currently poorly recognised) opportunity See Online/Comment http://dx.doi.org/10.1016/ health system that provides “access to quality essential to tackle underuse and overuse together to achieve the S0140-6736(16)32570-3, and health-care services and access to safe, effective, quality right care for health and wellbeing. http://dx.doi.org/10.1016/ S0140-6736(16)32573-9 and affordable essential medicines and vaccines for all”, What is right care? In its simplest definition it is care See Online/Series 1 as described in Sustainable Development Goal 3.8. that weighs up benefits and harms, is patient-centred http://dx.doi.org/10.1016/PII, Even many high-income countries, such as the USA (taking individual circumstances, values, and wishes http://dx.doi.org/10.1016/ S0140-6736(16)32379-0, and the UK, see important inequalities in income, life into account), and is informed by evidence, including http://dx.doi.org/10.1016/ expectancy, and health outcomes,2,3 and the prevailing cost-effectiveness.